UK-based healthcare company GlaxoSmithKline has kept backing one of its spin-outs, Autifony Therapeutics, which is researching treatments for hearing problems, retaining a stake after it raised a £10m ($16.5m) funding round.

GlaxoSmithKline will receive a 25.4% minority equity stake, and invest £1.25m. Autifony also raised the series A round from the Imperial Innovations Group,an Aim-listed investment trust founded by UK university Imperial College London, and venture firm SV Life Sciences. Imperial Innovations invested £5m to take a 33.6% stake…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?